Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers

Oncotarget

Volumn 5, Issue 10, 2014, Pages 3375-3385

  Sun, Chong Kui ^a,b   Zhang, Fan ^a   Xiang, Tao ^a   Chen, Qianming ^b   Pandita, Tej K ^c   Huang, Yuping ^d   Hu, Mickey C T ^e   Yang, Qin ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SICHUAN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d Sigma Aldrich Co   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA1; MTOR; PARP inhibitor; Rapamycin; S6

Indexed keywords

BRCA1 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PROTEIN S6; RAPAMYCIN; ANTINEOPLASTIC AGENT; BRAP PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRCA1 DEFICIENT CANCER; BREAST CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOUSE; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; DEFICIENCY; DRUG RESISTANCE; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; GENE TARGETING; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCK-IN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; PHOSPHORYLATION; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; RIBOSOMAL PROTEIN S6; SIROLIMUS; UBIQUITIN-PROTEIN LIGASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902076522     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1952     Document Type: Article

References (42)

1. Thompson, M.E., Jensen, R.A., Obermiller, P.S., Page, D.L., and Holt, J.T. (1995) Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat.Genet., 9, 444-450.
2. Narod, S.A. and Foulkes, W.D. (2004) BRCA1 and BRCA2: 1994 and beyond. Nat.Rev.Cancer, 4, 665-676.
3. Yu, X., Chini, C.C., He, M., Mer, G., and Chen, J. (2003) The BRCT domain is a phospho-protein binding domain. Science, 302, 639-642.
4. Manke, I.A., Lowery, D.M., Nguyen, A., and Yaffe, M.B. (2003) BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science, 302, 636-639.
5. Ludwig, T., Fisher, P., Ganesan, S., and Efstratiadis, A. (2001) Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev., 15, 1188-1193.
6. Williams, R.S., Lee, M.S., Hau, D.D., and Glover, J.N. (2004) Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat.Struct.Mol.Biol., 11, 519-525.
7. Zhang, J. and Powell, S.N. (2005) The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol.Cancer Res., 3, 531-539.
8. Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., Martin, N.M., Jackson, S.P., Smith, G.C., and Ashworth, A. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917-921.
9. Thompson, L.H. and Schild, D. (2001) Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat.Res., 477, 131-153.
10. Kennedy, R.D., Quinn, J.E., Mullan, P.B., Johnston, P.G., and Harkin, D.P. (2004) The role of BRCA1 in the cellular response to chemotherapy. J.Natl.Cancer Inst., 96, 1659-1668.
11. Moynahan, M.E., Chiu, J.W., Koller, B.H., and Jasin, M. (1999) Brca1 controls homology-directed DNA repair. Mol.Cell, 4, 511-518.
12. Scully, R., Ganesan, S., Vlasakova, K., Chen, J., Socolovsky, M., and Livingston, D.M. (1999) Genetic analysis of BRCA1 function in a defined tumor cell line. Mol.Cell, 4, 1093-1099.
13. Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M.J., Ashworth, A., Carmichael, J., Kaye, S.B., Schellens, J.H., and de Bono, J.S. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N.Engl.J.Med., 361, 123-134.
14. Fong, P.C., Yap, T.A., Boss, D.S., Carden, C.P., Mergui-Roelvink, M., Gourley, C., De, G.J., Lubinski, J., Shanley, S., Messiou, C., A'Hern, R., Tutt, A., Ashworth, A., Stone, J., Carmichael, J., Schellens, J.H., de Bono, J.S., and Kaye, S.B. (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J.Clin.Oncol., %20;28, 2512-2519.
15. Johnson, N., Johnson, S.F., Yao, W., Li, Y.C., Choi, Y.E., Bernhardy, A.J., Wang, Y., Capelletti, M., Sarosiek, K.A., Moreau, L.A., Chowdhury, D., Wickramanayake, A., Harrell, M.I., Liu, J.F., D'Andrea, A.D., Miron, A., Swisher, E.M., and Shapiro, G.I. (2013) Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc.Natl.Acad.Sci.U.S.A., 110, 17041-17046.
16. Norquist, B., Wurz, K.A., Pennil, C.C., Garcia, R., Gross, J., Sakai, W., Karlan, B.Y., Taniguchi, T., and Swisher, E.M. (2011) Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J.Clin.Oncol., 29, 3008-3015.
17. Dhillon, K.K., Swisher, E.M., and Taniguchi, T. (2011) Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci., 102, 663-669.
18. Swisher, E.M., Sakai, W., Karlan, B.Y., Wurz, K., Urban, N., and Taniguchi, T. (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res., 68, 2581-2586.
19. Bouwman, P. and Jonkers, J. (2014) Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors? Clin.Cancer Res., 20, 540-547.
20. Bouwman, P. and Jonkers, J. (2012) The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat.Rev.Cancer., 12, 587-598.
21. Jia, Y., Song, W., Zhang, F., Yan, J., and Yang, Q. (2013) Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway. Oncogene., 32, 1943-1949.
22. Xiang, T., Ohashi, A., Huang, Y., Pandita, T.K., Ludwig, T., Powell, S.N., and Yang, Q. (2008) Negative Regulation of AKT Activation by BRCA1. Cancer Res., 68, 10040-10044.
23. Xiang, T., Jia, Y., Sherris, D., Li, S., Wang, H., Lu, D., and Yang, Q. (2011) Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene.
24. Chen, F., Pruett-Miller, S.M., Huang, Y., Gjoka, M., Duda, K., Taunton, J., Collingwood, T.N., Frodin, M., and Davis, G.D. (2011) High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat.Methods., 8, 753-755.
25. Chen, J.J., Silver, D., Cantor, S., Livingston, D.M., and Scully, R. (1999) BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res., 59, 1752s-1756s.
26. Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., and Livingston, D.M. (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell, 88, 265-275.
27. Bhattacharyya, A., Ear, U.S., Koller, B.H., Weichselbaum, R.R., and Bishop, D.K. (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J.Biol Chem., 275, 23899-23903.
28. Khalaileh, A., Dreazen, A., Khatib, A., Apel, R., Swisa, A., Kidess-Bassir, N., Maitra, A., Meyuhas, O., Dor, Y., and Zamir, G. (2013) Phosphorylation of ribosomal protein S6 attenuates DNA damage and tumor suppression during development of pancreatic cancer. Cancer Res., 73, 1811-1820.
29. Yin, Y. and Shen, W.H. (2008) PTEN: a new guardian of the genome. Oncogene., 27, 5443-5453.
30. Shen, W.H., Balajee, A.S., Wang, J., Wu, H., Eng, C., Pandolfi, P.P., and Yin, Y. (2007) Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell., 128, 157-170.
31. Juvekar, A., Burga, L.N., Hu, H., Lunsford, E.P., Ibrahim, Y.H., Balmana, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C.A., Nardella, C., Pandolfi, P.P., Baselga, J., Scully, R., Asara, J.M., Cantley, L.C., and Wulf, G.M. (2012) Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov., 2, 1048-1063.
32. Bunting, S.F., Callen, E., Wong, N., Chen, H.T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., Xu, X., Deng, C.X., Finkel, T., Nussenzweig, M., Stark, J.M., and Nussenzweig, A. (2010) 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell, 141, 243-254.
33. Bouwman, P., Aly, A., Escandell, J.M., Pieterse, M., Bartkova, J., van der, G.H., Hiddingh, S., Thanasoula, M., KulKarni, A., Yang, Q., Haffty, B.G., Tommiska, J., Blomqvist, C., Drapkin, R., Adams, D.J., Nevanlinna, H., Bartek, J., Tarsounas, M., Ganesan, S., and Jonkers, J. (2010) 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat.Struct.Mol Biol, 17, 688-695.
34. Jaspers, J.E., Kersbergen, A., Boon, U., Sol, W., van, D.L., Zander, S.A., Drost, R., Wientjens, E., Ji, J., Aly, A., Doroshow, J.H., Cranston, A., Martin, N.M., Lau, A., O'Connor, M.J., Ganesan, S., Borst, P., Jonkers, J., and Rottenberg, S. (2013) Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov., 3, 68-81.
35. Oplustilova, L., Wolanin, K., Mistrik, M., Korinkova, G., Simkova, D., Bouchal, J., Lenobel, R., Bartkova, J., Lau, A., O'Connor, M.J., Lukas, J., and Bartek, J. (2012) Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle., 11, 3837-3850.
36. Chauvin, C., Koka, V., Nouschi, A., Mieulet, V., Hoareau-Aveilla, C., Dreazen, A., Cagnard, N., Carpentier, W., Kiss, T., Meyuhas, O., and Pende, M. (2014) Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene., 33, 474-483.
37. Ruvinsky, I., Katz, M., Dreazen, A., Gielchinsky, Y., Saada, A., Freedman, N., Mishani, E., Zimmerman, G., Kasir, J., and Meyuhas, O. (2009) Mice deficient in ribosomal protein S6 phosphorylation suffer from muscle weakness that reflects a growth defect and energy deficit. PLoS.One., %19;4, e5618.
38. Yang, Q., Zheng, Y.L., and Harris, C.C. (2005) POT1 and TRF2 cooperate to maintain telomeric integrity. Mol.Cell Biol., 25, 1070-1080.
39. Zeng, S., Xiang, T., Pandita, T.K., Gonzalez-Suarez, I., Gonzalo, S., Harris, C.C., and Yang, Q. (2009) Telomere recombination requires the MUS81 endonuclease. Nat.Cell Biol., 11, 616-623.
40. Yang, Q., Zhang, R., Horikawa, I., Fujita, K., Afshar, Y., Kokko, A., Laiho, P., Aaltonen, L.A., and Harris, C.C. (2007) Functional diversity of human protection of telomeres 1 isoforms in telomere protection and cellular senescence. Cancer Res., 67, 11677-11686.
41. Yang, Q., Zhang, R., Wang, X.W., Linke, S.P., Sengupta, S., Hickson, I.D., Pedrazzi, G., Perrera, C., Stagljar, I., Littman, S.J., Modrich, P., and Harris, C.C. (2004) The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase. Oncogene, 23, 3749-3756.
42. Zeng, S. and Yang, Q. (2009) The MUS81 endonuclease is essential for telomerase negative cell proliferation. Cell Cycle, 8, 2157-2160.